Literature DB >> 7495112

Washington University experience with extracorporeal shock-wave lithotripsy of pancreatic duct calculi.

J S Wolf1, S Y Nakada, G Aliperti, S A Edmundowicz, R V Clayman.   

Abstract

OBJECTIVES: To ascertain the effectiveness and safety of extracorporeal shock-wave lithotripsy (ESWL) for pancreatic calculi.
METHODS: Fourteen ESWL treatments were performed in 12 patients with chronic pancreatitis.
RESULTS: Fragmentation was perceptible after 13 of 14 treatments. Subsequent endoscopic manipulation resulted in complete extraction, partial extraction, and failed extraction of the fragments after 7, 4, and 2 of the ESWL treatments, respectively. No complications occurred and no patient had pancreatitis following ESWL. At a median follow-up of 19 to 22 months, 4 patients have had complete relief of symptoms, 4 have had a decrease in both severity and frequency of pain, and 4 have had no improvement.
CONCLUSIONS: ESWL is a safe and useful noninvasive adjunct in the treatment of patients with pancreatic duct calculi.

Entities:  

Mesh:

Year:  1995        PMID: 7495112     DOI: 10.1016/s0090-4295(99)80292-1

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  3 in total

1.  Endoscopic management of chronic pancreatitis.

Authors:  Veeral M Oza; Michel Kahaleh
Journal:  World J Gastrointest Endosc       Date:  2013-01-16

2.  Percutaneous cholangioscopy for the treatment of choledocho-lithiasis.

Authors:  Tiago Kojun Tibana; Renata Motta Grubert; Carlos Marcelo Dotti Rodrigues da Silva; Vinícius Adami Vayego Fornazari; Thiago Franchi Nunes
Journal:  Radiol Bras       Date:  2019 Sep-Oct

Review 3.  Percutaneous treatment of complex biliary stone disease using endourological technique and literature review.

Authors:  Fernando Korkes; Ariê Carneiro; Felipe Nasser; Breno Boueri Affonso; Francisco Leonardo Galastri; Marcos Belotto de Oliveira; Antônio Luiz de Vasconcellos Macedo
Journal:  Einstein (Sao Paulo)       Date:  2015-06-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.